277 related articles for article (PubMed ID: 32234809)
1. Proteasome Inhibitors Bortezomib and Carfilzomib Stimulate the Transport Activity of Human Organic Anion Transporter 1.
Fan Y; You G
Mol Pharmacol; 2020 Jun; 97(6):384-391. PubMed ID: 32234809
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of proteasome, but not lysosome, upregulates organic anion transporter 3 in vitro and in vivo.
Fan Y; Wang H; Yu Z; Liang Z; Li Y; You G
Biochem Pharmacol; 2023 Feb; 208():115387. PubMed ID: 36549459
[TBL] [Abstract][Full Text] [Related]
3. Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner.
Alam K; Farasyn T; Crowe A; Ding K; Yue W
PLoS One; 2017; 12(11):e0186924. PubMed ID: 29107984
[TBL] [Abstract][Full Text] [Related]
4. In-depth proteomic analysis of proteasome inhibitors bortezomib, carfilzomib and MG132 reveals that mortality factor 4-like 1 (MORF4L1) protein ubiquitylation is negatively impacted.
Porras-Yakushi TR; Reitsma JM; Sweredoski MJ; Deshaies RJ; Hess S
J Proteomics; 2021 Jun; 241():104197. PubMed ID: 33848640
[TBL] [Abstract][Full Text] [Related]
5. Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97.
Sha Z; Goldberg AL
Curr Biol; 2014 Jul; 24(14):1573-1583. PubMed ID: 24998528
[TBL] [Abstract][Full Text] [Related]
6. Combination of Second-Generation Proteasome Inhibitor Carfilzomib with Bortezomib in Four Different Breast Cancer Cell Lines.
Altundag EM; Yilmaz AM; Sahin A; Yilmaz BK
Anticancer Agents Med Chem; 2022 Aug; 22(16):2909-2918. PubMed ID: 35352669
[TBL] [Abstract][Full Text] [Related]
7. Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity.
Hasinoff BB; Patel D
Arch Biochem Biophys; 2017 Nov; 633():23-28. PubMed ID: 28887129
[TBL] [Abstract][Full Text] [Related]
8. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
[TBL] [Abstract][Full Text] [Related]
9. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
10. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
11. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
12. Regulation of RIPK3- and RHIM-dependent Necroptosis by the Proteasome.
Moriwaki K; Chan FK
J Biol Chem; 2016 Mar; 291(11):5948-5959. PubMed ID: 26786097
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
[TBL] [Abstract][Full Text] [Related]
14. Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells.
Singh V; Sharma V; Verma V; Pandey D; Yadav SK; Maikhuri JP; Gupta G
Eur J Nutr; 2015 Dec; 54(8):1255-67. PubMed ID: 25408199
[TBL] [Abstract][Full Text] [Related]
15. A High-Content Screening Assay for the Discovery of Novel Proteasome Inhibitors from Formosan Soft Corals.
Ling XH; Wang SK; Huang YH; Huang MJ; Duh CY
Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30347865
[TBL] [Abstract][Full Text] [Related]
16. The Proteasome as a Drug Target in the Metazoan Pathogen,
Bibo-Verdugo B; Wang SC; Almaliti J; Ta AP; Jiang Z; Wong DA; Lietz CB; Suzuki BM; El-Sakkary N; Hook V; Salvesen GS; Gerwick WH; Caffrey CR; O'Donoghue AJ
ACS Infect Dis; 2019 Oct; 5(10):1802-1812. PubMed ID: 31355632
[TBL] [Abstract][Full Text] [Related]
17. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Deshmukh RR; Kim S; Elghoul Y; Dou QP
J Cell Biochem; 2017 May; 118(5):1239-1248. PubMed ID: 27813130
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells.
Dasgupta S; Castro LM; Dulman R; Yang C; Schmidt M; Ferro ES; Fricker LD
PLoS One; 2014; 9(7):e103604. PubMed ID: 25079948
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
Mitsiades CS
J Clin Oncol; 2015 Mar; 33(7):782-5. PubMed ID: 25605842
[No Abstract] [Full Text] [Related]
20. Effective targeting of primitive AML CD34+ cells by the second-generation proteasome inhibitor carfilzomib.
van der Helm LH; Bosman MC; Schuringa JJ; Vellenga E
Br J Haematol; 2015 Nov; 171(4):652-5. PubMed ID: 25873108
[No Abstract] [Full Text] [Related]
[Next] [New Search]
